Total Payments
$478,769
2024 Payments
$61,100
Companies
43
Transactions
887
Medicare Patients
1,754
Medicare Billing
$148,180
Payment Breakdown by Category
Other$289,565 (60.5%)
Consulting$118,500 (24.8%)
Travel$51,148 (10.7%)
Food & Beverage$19,260 (4.0%)
Education$151.26 (0.0%)
Research$144.86 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $167,472 | 56 | 35.0% |
| Consulting Fee | $118,500 | 38 | 24.8% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $60,400 | 19 | 12.6% |
| Travel and Lodging | $51,148 | 150 | 10.7% |
| Honoraria | $29,353 | 18 | 6.1% |
| Compensation for serving as faculty or as a speaker for a medical education program | $19,380 | 8 | 4.0% |
| Food and Beverage | $19,260 | 592 | 4.0% |
| Grant | $12,960 | 1 | 2.7% |
| Education | $151.26 | 3 | 0.0% |
| Unspecified | $144.86 | 2 | 0.0% |
Payments by Type
General
$478,624
885 transactions
Research
$144.86
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Intercept Pharmaceuticals, Inc. | $146,921 | 141 | $0 (2024) |
| ABBVIE INC. | $127,927 | 275 | $0 (2024) |
| Gilead Sciences, Inc. | $122,393 | 150 | $0 (2024) |
| Merck Sharp & Dohme LLC | $55,643 | 61 | $0 (2024) |
| Ipsen Biopharmaceuticals, Inc | $13,005 | 8 | $0 (2024) |
| ORPHALAN INC | $3,194 | 3 | $0 (2023) |
| GlaxoSmithKline, LLC. | $2,600 | 1 | $0 (2023) |
| Madrigal Pharmaceuticals | $2,195 | 3 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,043 | 47 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $926.83 | 53 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $61,100 | 78 | Gilead Sciences, Inc. ($20,373) |
| 2023 | $36,605 | 81 | INTERCEPT PHARMACEUTICALS, INC. ($29,270) |
| 2022 | $2,532 | 56 | INTERCEPT PHARMACEUTICALS, INC. ($1,340) |
| 2021 | $7,719 | 53 | Intercept Pharmaceuticals, Inc. ($4,187) |
| 2020 | $27,318 | 40 | Gilead Sciences, Inc. ($13,077) |
| 2019 | $75,942 | 147 | Intercept Pharmaceuticals, Inc. ($36,503) |
| 2018 | $124,553 | 203 | Intercept Pharmaceuticals, Inc. ($49,511) |
| 2017 | $143,001 | 229 | Gilead Sciences Inc ($53,506) |
All Payment Transactions
887 individual payment records from CMS Open Payments — Page 1 of 36
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,115.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/08/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,046.00 | General |
| Category: Rare Disease | ||||||
| 12/02/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $18.55 | General |
| Category: LIVER DISEASE | ||||||
| 11/27/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Honoraria | Cash or cash equivalent | $2,523.00 | General |
| Category: Rare Disease | ||||||
| 11/25/2024 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $21.87 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 11/18/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $39.87 | General |
| Category: VIROLOGY | ||||||
| 11/17/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Rare Disease | ||||||
| 11/17/2024 | Gilead Sciences, Inc. | Livdelzi (Drug) | Food and Beverage | In-kind items and services | $49.73 | General |
| Category: INFLAM | ||||||
| 11/16/2024 | Gilead Sciences, Inc. | Livdelzi (Drug) | Food and Beverage | In-kind items and services | $85.31 | General |
| Category: INFLAM | ||||||
| 11/16/2024 | Ipsen Biopharmaceuticals, Inc | Bylvay (Drug) | Food and Beverage | In-kind items and services | $71.18 | General |
| Category: Gastroenterology | ||||||
| 11/15/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $124.91 | General |
| 11/15/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $61.79 | General |
| Category: LIVER DISEASE | ||||||
| 11/14/2024 | Gilead Sciences, Inc. | Livdelzi (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,790.00 | General |
| Category: INFLAM | ||||||
| 11/13/2024 | Gilead Sciences, Inc. | Livdelzi (Drug) | Food and Beverage | In-kind items and services | $140.53 | General |
| Category: INFLAM | ||||||
| 11/11/2024 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Food and Beverage | In-kind items and services | $16.90 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/30/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $19.22 | General |
| Category: IMMUNOLOGY | ||||||
| 10/28/2024 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $25.66 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 10/23/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $14.34 | General |
| Category: Gastroenterology | ||||||
| 10/21/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $25.75 | General |
| Category: INTERNAL MEDICINE | ||||||
| 10/18/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug) | Food and Beverage | In-kind items and services | $17.19 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/12/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $25.52 | General |
| Category: Rare Disease | ||||||
| 10/03/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $21.88 | General |
| Category: VIROLOGY | ||||||
| 09/26/2024 | Gilead Sciences, Inc. | Livdelzi (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,930.00 | General |
| Category: INFLAM | ||||||
| 09/24/2024 | Gilead Sciences, Inc. | Livdelzi (Drug) | Travel and Lodging | In-kind items and services | $767.94 | General |
| Category: INFLAM | ||||||
| 09/24/2024 | Gilead Sciences, Inc. | Livdelzi (Drug) | Food and Beverage | In-kind items and services | $116.95 | General |
| Category: INFLAM | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| STELLAR-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis | Gilead Sciences, Inc. | $144.86 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 477 | 515 | $303,774 | $40,537 |
| 2022 | 12 | 462 | 496 | $294,248 | $38,278 |
| 2021 | 11 | 467 | 507 | $292,280 | $41,915 |
| 2020 | 9 | 348 | 365 | $191,102 | $27,450 |
Total Patients
1,754
Total Services
1,883
Medicare Billing
$148,180
Procedure Codes
44
All Medicare Procedures & Services
44 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 53 | 53 | $97,506 | $11,478 | 11.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 74 | 85 | $29,776 | $8,216 | 27.6% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 21 | 21 | $20,640 | $3,858 | 18.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 36 | 41 | $10,186 | $2,979 | 29.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 12 | 27 | $7,269 | $2,647 | 36.4% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 30 | 30 | $36,890 | $2,472 | 6.7% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 20 | 20 | $35,776 | $2,313 | 6.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 19 | 19 | $8,605 | $2,045 | 23.8% |
| 91200 | Measurement of liver stiffness | Office | 2023 | 55 | 58 | $6,135 | $1,448 | 23.6% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 16 | 16 | $25,292 | $1,430 | 5.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 12 | 12 | $3,662 | $1,048 | 28.6% |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | Facility | 2023 | 129 | 133 | $22,036 | $604.85 | 2.7% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 53 | 53 | $97,415 | $10,573 | 10.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 65 | 69 | $24,174 | $6,829 | 28.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 20 | 43 | $11,577 | $3,661 | 31.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 44 | 46 | $11,426 | $3,525 | 30.9% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2022 | 13 | 13 | $12,766 | $2,514 | 19.7% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 27 | 27 | $33,100 | $2,316 | 7.0% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 19 | 19 | $33,974 | $1,951 | 5.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 15 | 15 | $6,789 | $1,868 | 27.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 19 | 19 | $5,799 | $1,761 | 30.4% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 20 | 20 | $31,524 | $1,505 | 4.8% |
| 91200 | Measurement of liver stiffness | Office | 2022 | 45 | 47 | $4,975 | $1,241 | 24.9% |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | Facility | 2022 | 122 | 125 | $20,729 | $533.35 | 2.6% |
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Facility | 2021 | 45 | 45 | $81,852 | $9,659 | 11.8% |
About Dr. Paul Pockros, M.D
Dr. Paul Pockros, M.D is a Gastroenterology healthcare provider based in La Jolla, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1124082748.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Paul Pockros, M.D has received a total of $478,769 in payments from pharmaceutical and medical device companies, with $61,100 received in 2024. These payments were reported across 887 transactions from 43 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($167,472).
As a Medicare-enrolled provider, Pockros has provided services to 1,754 Medicare beneficiaries, totaling 1,883 services with total Medicare billing of $148,180. Data is available for 4 years (2020–2023), covering 44 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location La Jolla, CA
- Active Since 04/12/2006
- Last Updated 06/29/2009
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1124082748
Products in Payments
- OCALIVA (Drug) $130,103
- Mavyret (Drug) $66,567
- Epclusa (Drug) $51,288
- ZEPATIER (Drug) $45,519
- Viekira (Drug) $39,380
- MAVYRET (Drug) $20,413
- IQIRVO (Drug) $12,934
- Livdelzi (Drug) $9,880
- Vosevi (Drug) $7,187
- OCA (Drug) $4,518
- Vemlidy (Drug) $3,467
- CUVRIOR (Drug) $3,194
- REZDIFFRA (Drug) $2,115
- XIFAXAN (Drug) $1,045
- ENTYVIO (Biological) $613.50
- STELARA (Biological) $331.02
- LINZESS (Drug) $327.91
- Humira (Biological) $327.27
- XELJANZ (Drug) $284.75
- RINVOQ (Biological) $259.12
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in La Jolla
Dr. Catherine Frenette, M.d, M.D
Gastroenterology — Payments: $672,212
Gastroenterology $672,212
Dr. Quan Nhu, M.d., Ph.d, M.D., PH.D
Gastroenterology — Payments: $498,895
Gastroenterology $498,895
Dr. Walter Coyle, M.d, M.D
Gastroenterology — Payments: $241,005
Gastroenterology $241,005
Dr. Adam Deising, D.o, D.O
Gastroenterology — Payments: $86,643
Gastroenterology $86,643
Dr. Sushrut Thiruvengadam, M.d, M.D
Gastroenterology — Payments: $51,904
Gastroenterology $51,904
Syed Fehmi, M.d., M.s, M.D., M.S
Gastroenterology — Payments: $19,681
Gastroenterology $19,681